SomnoMed Limited (ASX:SOM)

Market Cap	131.45M +35.2%
Revenue (ttm)	118.50M +18.2%
Net Income	-2.56M
EPS	-0.01
Shares Out	219.08M
PE Ratio	n/a
Forward PE	27.15
Dividend	n/a
Ex-Dividend Date	n/a

Volume	182,403
Open	0.6000
Previous Close	0.6000
Day's Range	0.5900 - 0.6020
52-Week Range	0.5000 - 0.9450
Beta	0.81
Analysts	Strong Buy
Price Target	1.03 (+71.67%)
Earnings Date	Feb 26, 2026

About SomnoMed

SomnoMed Limited, together with its subsidiaries, produce and sells devices for the oral treatment of sleep related disorders in the Asia Pacific region, North America, and Europe. It provides SomnoDent Avant, as well as SomnoDent Classic, SomnoDent Flex, and SomnoDent Fusion are offered for the treatment of obstructive sleep apnea. The company also offers SomMorning Repositioner, a product designed to help return patient’s mandible back to its pre-treatment centric position; SomnoBrux splint, a custom fit, acrylic splint for patient’s upper te...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1987
• Employees: 300
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: SOM

Financial Performance

In fiscal year 2025, SomnoMed's revenue was 111.49 million, an increase of 21.65% compared to the previous year's 91.65 million. Losses were -3.46 million, -71.77% less than in 2024.

Analyst Summary

According to 3 analysts, the average rating for SOM stock is "Strong Buy." The 12-month stock price target is $1.03, which is an increase of 71.67% from the latest price.

Price Target

$1.03

(71.67% upside)

Analyst Consensus: Strong Buy